Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout
Tilray Brands shares surged December 15 as global cannabis stocks rallied on reports that Donald Trump may push to reclassify marijuana as a Schedule III drug. The move, which would ease federal restrictions but stop short of legalization, fueled investor optimism over potential tax and banking benefits for the industry. Tilray also completed a 1-for-10 reverse stock split and reported momentum in its Canadian portfolio.